BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38393328)

  • 21. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
    Kouverianos I; Angelopoulos A; Daoussis D
    Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
    Nair P; Wenzel S; Rabe KF; Bourdin A; Lugogo NL; Kuna P; Barker P; Sproule S; Ponnarambil S; Goldman M;
    N Engl J Med; 2017 Jun; 376(25):2448-2458. PubMed ID: 28530840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early add-on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis.
    Ikeda T; Komatsu T; Yokoyama K; Takahashi K; Kawakami T
    J Dermatol; 2021 Apr; 48(4):529-532. PubMed ID: 33305381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
    Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
    Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
    Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
    Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
    Puéchal X; Pagnoux C; Baron G; Quémeneur T; Néel A; Agard C; Lifermann F; Liozon E; Ruivard M; Godmer P; Limal N; Mékinian A; Papo T; Ruppert AM; Bourgarit A; Bienvenu B; Geffray L; Saraux JL; Diot E; Crestani B; Delbrel X; Sailler L; Cohen P; Le Guern V; Terrier B; Groh M; Le Jeunne C; Mouthon L; Ravaud P; Guillevin L;
    Arthritis Rheumatol; 2017 Nov; 69(11):2175-2186. PubMed ID: 28678392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
    Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
    Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
    Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
    Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
    Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
    Bettiol A; Urban ML; Padoan R; Groh M; Lopalco G; Egan A; Cottin V; Fraticelli P; Crimi C; Del Giacco S; Losappio L; Moi L; Cinetto F; Caminati M; Novikov P; Berti A; Cameli P; Cathébras P; Coppola A; Durel CA; Folci M; Lo Gullo A; Lombardi C; Monti S; Parronchi P; Rivera CM; Solans R; Vacca A; Espígol-Frigolé G; Guarnieri G; Bianchi FC; Marchi MR; Tcherakian C; Kahn JE; Iannone F; Venerito V; Desaintjean C; Moroncini G; Nolasco S; Costanzo GAML; Schroeder JW; Ribi C; Tesi M; Gelain E; Mattioli I; Bello F; Jayne D; Prisco D; Vaglio A; Emmi G;
    Lancet Rheumatol; 2023 Dec; 5(12):e707-e715. PubMed ID: 38251561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
    N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    McBrien CN; Menzies-Gow A
    Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Pagnoux C; Groh M
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
    Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
    Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
    Wechsler ME; Fan Y; Merkel PA
    N Engl J Med; 2024 May; 390(20):1940. PubMed ID: 38810204
    [No Abstract]   [Full Text] [Related]  

  • 37. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
    Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
    Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benralizumab for
    Kuang FL; Legrand F; Makiya M; Ware J; Wetzler L; Brown T; Magee T; Piligian B; Yoon P; Ellis JH; Sun X; Panch SR; Powers A; Alao H; Kumar S; Quezado M; Yan L; Lee N; Kolbeck R; Newbold P; Goldman M; Fay MP; Khoury P; Maric I; Klion AD
    N Engl J Med; 2019 Apr; 380(14):1336-1346. PubMed ID: 30943337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
    Matsuno O; Minamoto S
    Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.